Doonan, J. et al. (2018) Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 23(10), 2669. (doi: 10.3390/molecules23102669) (PMID:30336585) (PMCID:PMC6222842)

Suckling, C. J., Alam, S., Olson, M. A., Saikh, K. U., Harnett, M. M. and Harnett, W. (2018) Small Molecule Analogues of the parasitic worm product ES-62 interact with the TIR domain of MyD88 to inhibit pro-inflammatory signalling. Scientific Reports, 8, 2123. (doi: 10.1038/s41598-018-20388-z) (PMID:29391452) (PMCID:PMC5794923)

Janicova, L., Rzepecka, J., Rodgers, D.T., Doonan, J., Bell, K.S., Lumb, F.E., Suckling, C.J., Harnett, M.M. and Harnett, W. (2016) Testing small molecule analogues of theAcanthocheilonema viteaeimmunomodulator ES-62 against clinically relevant allergens. Parasite Immunology, 38(6), pp. 340-351. (doi: 10.1111/pim.12322) (PMID:27059010) (PMCID:PMC4913752)

Rzepecka, J. et al. (2015) Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome. Journal of Autoimmunity, 60, pp. 59-73. (doi: 10.1016/j.jaut.2015.04.005) (PMID:25975491) (PMCID:PMC4459730)